England opener Zak Crawley is confident about the team’s preparation as they head into the first Ashes Test against Australia at Perth Stadium next week, despite criticism from commentators and former players over England scheduling only one…
A new medical review has found that eating an orange daily may significantly reduce the risk of mouth, throat and stomach cancers.
The study, conducted in Australia, highlights the powerful nutrients packed inside…
China has advised its citizens to avoid travelling to Japan, escalating a diplomatic feud sparked by comments from Tokyo’s new prime minister about a hypothetical attack on Taiwan.
Sanae Takaichi told Japan’s parliament on 7 November that the…
Unlock the Editor’s Digest for free
Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter.
Apple is stepping up its succession planning efforts, as it prepares for Tim Cook to step down as chief executive as soon as next year.
Several people familiar with discussions inside the tech group told the Financial Times that its board and senior executives have recently intensified preparations for Cook to hand over the reins at the $4tn company after more than 14 years.
John Ternus, Apple’s senior vice-president of hardware engineering, is widely seen as Cook’s most likely successor, although no final decisions have been made, these people said.
People close to Apple say the long-planned transition is not related to the company’s current performance, ahead of what is expected to be a blockbuster end-of-year sales period for the iPhone.
Apple declined to comment.
The company is unlikely to name a new CEO before its next earnings report in late January, which covers the critical holiday period.
An announcement early in the year would give its new leadership team time to settle in ahead of its big annual keynote events, its developer conference in June and its iPhone launch in September, the people said.
These people said that although preparations have intensified, the timing of any announcement could change.
Cook, Apple’s former operations chief who turned 65 this month, has led the company since 2011 when he took over the role from its co-founder Steve Jobs, who died months later. During Cook’s tenure, the Big Tech group’s market capitalisation has surged from about $350bn in 2011 to $4tn today.
Apple’s shares are trading close to an all-time high after strong results last month, although its stock-price rise of roughly 12 per cent this year lags behind its Big Tech rivals Alphabet, Nvidia and Microsoft, whose valuations have been propelled by Wall Street’s exuberance about artificial intelligence.
Apple has had a number of high-profile changes this year among its top executive team. Longtime Cook confidante, chief financial officer Luca Maestri, stepped back from his role at the start of this year. Jeff Williams, a Cook protégé, announced he was stepping down as chief operating officer in July.
Appointing Ternus would put an executive from the hardware side of the company back in charge at the iPhone maker at a time when Apple has struggled to break into new product categories and keep up with its Silicon Valley rivals in AI.
Cook has voiced his preference for an internal candidate to be chosen as his replacement, saying the company has “very detailed succession plans”.
“I love it there and I can’t envision my life without being there so I’ll be there a while,” he told singer Dua Lipa on her podcast in November 2023.
Brazil set out to host this year’s United Nations climate talks with a promise to spotlight Indigenous peoples whose way of life depends on the Amazon rainforest. Those groups are seizing the chance.
For the second time this week, Indigenous…
Ascletis Pharma announced new preclinical and Phase Ib clinical results for its portfolio of next-generation obesity drug candidates, including ASC36, ASC35, and ASC30, developed using its proprietary AISBDD and ULAP technologies.
A key highlight is the plan to submit a US Investigational New Drug Application in 2026 for a co-formulated monthly therapy that showed greater weight reduction in animal models compared to existing treatments.
We’ll explore how Ascletis Pharma’s advancement toward a US IND submission for its obesity treatment candidates could reshape its investment narrative.
AI is about to change healthcare. These 31 stocks are working on everything from early diagnostics to drug discovery. The best part – they are all under $10b in market cap – there’s still time to get in early.
For investors considering Ascletis Pharma, the core belief hinges on the company’s ability to break into the high-growth obesity treatment market with its new-generation drug candidates. The recent disclosure of strong preclinical and Phase Ib data for ASC36, ASC35, and ASC30, along with a planned US IND application for a co-formulated monthly obesity therapy, marks a potentially significant catalyst that could refresh sentiment and drive near-term share price momentum. This news adds clear visibility to the clinical pipeline, which has repeatedly faced skepticism due to historic unprofitability and regulatory hurdles. While the obesity portfolio’s progress could accelerate prospects and broaden Ascletis’ market appeal, key risks remain, especially related to clinical trial outcomes and the heavy investment demands required before potential commercialisation. Materially, these developments could shift attention from past earnings volatility toward future pipeline milestones as primary value drivers.
On the flip side, regulatory outcomes and patent risks remain critical concerns for shareholders. Upon reviewing our latest valuation report, Ascletis Pharma’s share price might be too optimistic.
The Simply Wall St Community offered one fair value estimate before this latest news event, suggesting very little variation in opinions at that time. While clinical trial advancements have improved pipeline visibility, actual commercial success depends on regulatory approvals and market uptake. Explore other views that may broaden your perspective on what could shape the company’s future.
Explore another fair value estimate on Ascletis Pharma – why the stock might be worth less than half the current price!
MDA Space (TSX:MDA) is making headlines after two major updates for investors: robust earnings for the quarter and year to date, along with a new partnership to advance wireless power systems for use in space.
See our latest analysis for MDA Space.
The share price has had a turbulent ride this year, with a sharp dip in recent months weighing on sentiment. Positive earnings and partnership news made headlines during this period. While the year-to-date share price return stands at -21.87%, long-term investors have still pocketed a 238.3% total shareholder return over the past three years. This points to significant gains for those who have stayed the course.
Curious what else is happening in the sector? You can explore other aerospace and defense innovators with strong momentum by checking out See the full list for free.
MDA Space’s recent results and high-profile partnership have caught investor attention, but with shares still well below analyst targets and strong revenue gains, is this a bargain opportunity or is future growth already priced in?
According to IndusyHoldings, the narrative puts MDA Space’s fair value at CA$44.08, nearly double the recent close. This sets the stage for an ambitious financial outlook.
MDA Space can benefit greatly from the tailwind of the industry as they offer a wide product range that includes LEO and MEO satellites, space robots and space rovers.
Read the complete narrative.
What’s the growth blueprint fueling that target price? The narrative’s secret sauce lies in bold projections about future revenue and profit margins. Want to know which key financial figures put this company in the spotlight? The full story breaks down the ambitious numbers that build this valuation case. Read on to see what’s driving it.
Result: Fair Value of $44.08 (UNDERVALUED)
Have a read of the narrative in full and understand what’s behind the forecasts.
However, heavy reliance on government contracts and potential Artemis delays could quickly overturn the optimistic outlook presented by current projections.
Find out about the key risks to this MDA Space narrative.
If you want to dig deeper or see things differently, you can analyze the data for yourself and shape your own view in just a few minutes. Do it your way
A great starting point for your MDA Space research is our analysis highlighting 5 key rewards and 1 important warning sign that could impact your investment decision.
Outsmart the ordinary by tapping into opportunities others might miss. Make your next move count by finding well-positioned stocks with just a few quick clicks below.
People often substitute fizzy drinks like cola for healthier drinks like Milk and fresh fruit juices. Thus, they get a lesser amount of minerals, proteins, and vitamins that would have been present if they had opted for healthier drinks. In a…
RIYADH (Saudi Arabia) (AFP) – Crown Prince Mohammed bin Salman will press for security guarantees while US President Donald Trump will urge him to normalise ties with Israel when the de facto Saudi ruler breaks a…
If you like playing daily word games like Wordle, then Hurdle is a great game to add to your routine.
There are five rounds to the game. The first round sees you trying to guess the…